# US 2003/0215820 A1 · Regulators of type-1tumor necrosis factor receptor and other cytokine receptor shedding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215820 A1
- Document ID: US20030215820A1
- Status: Published application
- Kind: A1
- Application number: 10/220,443
- Filed: 2002-12-19
- Published: 2003-11-20
- Earliest claimed: 2002-12-19
- Assignees: The United States of America as represented by the Department of Health and Human Services
- Inventors: Stewart Levine
- Web page: https://patentgrep.com/patent/US20030215820A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 16/40: against enzymes
- C12N 9/6421: {from mammals}
- C12N 15/1133: {against herpetoviridae, e.g. HSV}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides compositions and methods for the regulation of cytokine signaling through the Tumor Necrosis Factor (TNF) pathway. Specifically, the invention provides a novel gene, polypeptide and related compositions and methods for the regulation of ectodomain shedding. In preferred embodiments, methods and compositions for the regulation of TNF Type-1 Receptor ectodomain shedding are provided. The present invention finds use in therapeutics, diagnostics, and drug screening applications.

## Claims

### Claim 1

An isolated nucleic acid having the nucleotide sequence set forth in SEQ ID NO:1.

### Claim 2

An isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:2.

### Claim 3

An isolated nucleic acid encoding the polypeptide set forth in SEQ ID NO:2.

### Claim 4 (depends on 3)

A recombinant vector comprising the nucleic acid of claim 3.

### Claim 5 (depends on 4)

A host cell comprising the recombinant vector of claim 4, wherein said host cell is selected from the group consisting of prokaryotic host cells and eukaryotic host cells.

### Claim 6 (depends on 2)

An antibody directed against at least a portion of said polypeptide of claim 2, wherein said antibody is selected from the group consisting of monoclonal antibodies and polyclonal antibodies.

### Claim 7 (depends on 1)

An isolated nucleic acid substantially homologous to the nucleic acid of claim 1, wherein said nucleic acid is capable of hybridizing under high stringency conditions to the nucleic acid of claim 1.

### Claim 8 (depends on 7)

The isolated nucleic acid of claim 7, wherein said nucleic acid encodes a polypeptide having the ability to regulate the shedding of the extracellular domain of at least one cytokine receptor.

### Claim 9 (depends on 8)

The isolated nucleic acid of claim 8, wherein said cytokine receptor is selected from the group consisting of type-1 tumor necrosis factor receptor, type I interleukin-1 cytokine receptor, type II interleukin-1 cytokine receptor, and interleukin-6 cytokine receptor alpha-chain gp80.

### Claim 10 (depends on 1)

A method for the isolation of an amplifiable nucleic acid substantially homologous to the nucleic acid of claim 1, comprising:
a) providing:
i) a sample comprising template nucleic acid suspected of encoding a gene substantially homologous to the nucleic acid of claim 1, and
ii) at least two primers;
b) annealing said primers to said template nucleic acid;
c) extending said primers with reiterated DNA synthesis under conditions such that said template nucleic acid is amplified to produce an amplified product; and
d) visualizing and isolating said amplified product.

### Claim 11 (depends on 10)

The amplified product of claim 10.

### Claim 12 (depends on 11)

The amplified product of claim 11, wherein said amplified product encodes a polypeptide having the ability to regulate the shedding of the extracellular domain of at least one cytokine receptor.

### Claim 13 (depends on 12)

The amplified product of claim 12, wherein said cytokine receptor is selected from the group consisting of type-1 tumor necrosis factor receptor, type I interleukin-1 cytokine receptor, type II interleukin-1 cytokine receptor, and interleukin-6 cytokine receptor alpha-chain gp80.

### Claim 14 (depends on 3, 4)

A method for regulating the shedding of the extracellular domain of at least one cytokine receptor, comprising the steps of:
a) providing:
i) the recombinant vector of claim 4, wherein said vector comprises the nucleic acid of claim 3 in the sense orientation,
ii) a first tissue containing one or more cells expressing a cytokine receptor, and
iii) a second tissue comprising one or more cells capable of expressing the polypeptide encoded by said recombinant vector; and
b) delivering said vector to said cells of said second tissue in the presence of said first tissue, under conditions which result in regulation of shedding of said cytokine receptor from cells of said first tissue.

### Claim 15 (depends on 14)

The method of claim 14, wherein said cytokine receptor is selected from the group consisting of type-1 tumor necrosis factor receptor, type I interleukin-1 cytokine receptor, type II interleukin-1 cytokine receptor, and interleukin-6 cytokine receptor alpha-chain gp80.

### Claim 16 (depends on 14)

The method of claim 14, wherein said delivering said vector to said second tissue comprises a means of intracellular delivery selected from the group consisting of direct nucleic acid administration, liposome administration, viral vector delivery, and ex vivo gene delivery followed by transplantation.

### Claim 17 (depends on 1, 4)

A method for regulating the shedding of the extracellular domain of at least one cytokine receptor, comprising the steps of:
a) providing:
i) the recombinant vector of claim 4, wherein said recombinant vector comprises at least a transcribeable portion of the nucleic acid of claim 1 in an antisense orientation,
ii) a first tissue comprising one or more cells expressing a cytokine receptor, and
iii) a second tissue comprising one or more cells expressing the endogenous polypeptide of SEQ ID NO:2, and one or more cells capable of transcribing said antisense nucleic acid; and
b) delivering said vector to said second tissue in the presence of said first tissue, under conditions that result in regulation of shedding of said cytokine receptor from the cells of said first tissue.

### Claim 18 (depends on 17)

The method of claim 17, wherein said cytokine receptor is selected from the group consisting of type-1 tumor necrosis factor receptor, type I interleukin-1 cytokine receptor, type II interleukin-1 cytokine receptor, and interleukin-6 cytokine receptor alpha-chain gp80.

### Claim 19 (depends on 17)

The method of claim 17, wherein said delivering said vector to said second tissue comprises a means of intracellular delivery selected from the group consisting of direct nucleic acid administration, liposome administration, viral vector delivery, and ex vivo gene delivery followed by transplantation.

### Claim 20

A method for regulating the shedding of the extracellular domain of at least one cytokine receptor, comprising the steps of:
a) providing:
i) a polypeptide having the amino acid sequence set forth in SEQ ID NO:2, and
ii) a tissue comprising one or more cells expressing a cytokine receptor on their plasma membrane extracellular surface; and
b) delivering said polypeptide to said tissue under conditions such that said polypeptide regulates the shedding of the cytokine receptor from the surface of said cells of said tissue.

### Claim 21 (depends on 20)

The method of claim 20, wherein said cytokine receptor is selected from the group consisting of type-1 tumor necrosis factor receptor, type I interleukin-1 cytokine receptor, type II interleukin-1 cytokine receptor, and interleukin-6 cytokine receptor alpha-chain gp80.

### Claim 22 (depends on 20)

The method of claim 20, wherein said delivering said polypeptide to said tissue comprises a means of delivery selected from the group consisting of oral administration, intra-arterial injection, intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, suppository, local surgical administration, systemic surgical administration, catheter, and any combination of these means of delivery.

### Claim 23 (depends on 6)

A method for regulating the shedding of the extracellular domain of at least one cytokine receptor, comprising the steps of:
a) providing:
i) the antibody of claim 6, and
ii) a tissue comprising one or more cells expressing a cytokine receptor and the endogenous polypeptide of SEQ ID NO:2; and
b) delivering said antibody to said tissue under conditions such that said antibody regulates the shedding of said cytokine receptor from the surface of said cells of said tissue.

### Claim 24 (depends on 23)

The method of claim 23, wherein said cytokine receptor is selected from the group consisting of type-1 tumor necrosis factor receptor, type I interleukin-1 cytokine receptor, type II interleukin-1 cytokine receptor, and interleukin-6 cytokine receptor alpha-chain gp80.

### Claim 25 (depends on 23)

The method of claim 23, wherein said means of delivery is selected from the group consisting of oral administration, intra-arterial injection, intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, suppository, local surgical administration, systemic surgical administration, catheter, and any combination of these means of delivery.

### Claim 26 (depends on 1, 2, 3, 4, 6)

A method for treating a subject, comprising the steps of:
a) providing:
i) a composition selected from the group consisting of the recombinant vector of claim 4, wherein said vector contains the nucleic acid of claim 3 in the sense orientation, the recombinant vector of claim 4, wherein said vector contains at least a portion of said nucleic acid of claim 1 in the antisense orientation, the polypeptide of claim 2, and the antibody of claim 6,
ii) a subject, and
iii) a means of delivery of said composition to at least one tissue of said subject; and
b) delivering said composition to said subject using said means of delivery.

### Claim 27 (depends on 26)

The method of claim 26, wherein said subject is selected from the group consisting of a subject displaying pathology resulting from abnormal cytokine activity, a subject suspected of displaying pathology resulting from abnormal cytokine activity, and a subject at risk of displaying pathology resulting from abnormal cytokine activity.

### Claim 28 (depends on 27)

The method of claim 27, wherein said cytokine activity is mediated by a cytokine selected from the group consisting of tumor necrosis factor α, interleukin-1 alpha, interleukin-1 beta, and interleukin-6.

### Claim 29 (depends on 26)

The method of claim 26, wherein said subject is a human.

### Claim 30 (depends on 26)

The method of claim 26, wherein said means of delivery is selected from the group consisting of oral administration, intra-arterial injection, intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, suppository, local surgical administration, systemic surgical administration, catheter, and any combination of these means of delivery.

### Claim 31 (depends on 30)

The method of claim 30, wherein said means of delivery is further selected from the group consisting of direct nucleic acid administration, liposome administration, viral vector delivery, and ex vivo gene delivery followed by transplantation.

### Claim 32 (depends on 1)

A means for detecting an ARTS-1 mRNA in a sample, wherein said means comprises at least a portion of the nucleic acid of claim 1 complementary to at least a portion of said ARTS-1 mRNA, and further wherein said nucleic acid is a probe.

### Claim 33 (depends on 32)

The means of claim 32, wherein said means comprises Northern blotting.

### Claim 34 (depends on 32)

The means of claim 32, wherein said sample is a tissue sample from a subject.

### Claim 35 (depends on 6)

A means for detecting an ARTS-1 polypeptide in a sample, wherein said means comprises the antibody of claim 6.

### Claim 36 (depends on 35)

The means of claim 35, wherein said means comprises Western immunoblotting.

### Claim 37 (depends on 35)

The means of claim 35, wherein said means comprises an enzyme-linked immunosorbent assay.

### Claim 38 (depends on 35)

The means of claim 35, wherein said sample is a tissue sample from a subject.

### Claim 39 (depends on 32, 35)

A diagnostic kit comprising a means to measure ARTS-1 expression, wherein said means is selected from the group consisting of the means of claim 32 and claim 35.

### Claim 40 (depends on 32, 35)

A method for drug screening to identify drugs having the ability to regulate ARTS-1 expression comprising the steps of:
a) providing:
i) a drug,
ii) cultured cells, and
iii) a means to measure ARTS-1 expression, wherein said means is selected from the group consisting of the means of claim 32 and claim 35;
b) exposing said cells to said drug; and
c) using said means to measure ARTS-1 expression.

### Claim 41 (depends on 40)

The method of claim 40, wherein said cultured cells are human NCI-H292 pulmonary mucoepidermoid carcinoma cells.

### Claim 42

A method for drug screening to identify drugs capable of regulating the peptidase activity of ARTS-1, comprising the steps of:
a) providing:
i) purified ARTS-1 polypeptide,
ii) an amino acid p-nitroaniline,
iii) a means to measure amino acid p-nitroaniline cleavage, and
iv) a drug;
b) exposing said purified ARTS-1 polypeptide to said amino acid p-nitroaniline in the absence and presence of said drug; and
c) measuring amino acid p-nitroaniline cleavage in the absence and presence of said drug.

### Claim 43 (depends on 42)

The method of claim 42, wherein said purified ARTS-1 polypeptide comprises glutathione-S-transferase.

### Claim 44 (depends on 42)

The method of claim 42, wherein said amino acid p-nitroaniline is selected from the group consisting of isoleucine p-nitroanilide, phenylalanine p-nitroanilide and glycine p-nitroanilide.

### Claim 45 (depends on 42)

The method of claim 42, wherein said means to measure amino acid p-nitroaniline cleavage comprises measuring absorbance at 380 nm.

### Claim 46

A method for drug screening to identify drugs capable of regulating the shedding of a cytokine receptor, comprising the steps of:
a) providing:
i) cultured cells expressing a cytokine receptor,
ii) a means to quantitate the concentration of the soluble form of said cytokine receptor in the supernatants of said cultured cells, and
iii) a drug;
b) culturing said cells in the absence and presence of said drug;
c) quantitating the concentration of said soluble form of said cytokine receptor in said supernatants of said cultured cells using said means; and
d) comparing the concentrations of said soluble cytokine receptor in said supernatants of said cell cultures in the absence and presence of drug.

### Claim 47 (depends on 46)

The method of claim 46, wherein said cytokine receptor is selected from the group consisting of type-1 tumor necrosis factor receptor, type II interleukin-1 cytokine receptor, and interleukin-6 cytokine receptor alpha-chain gp80.

### Claim 48 (depends on 46)

The method of claim 46, wherein said means to quantitate the concentration of the soluble form of a cytokine receptor is an enzyme-linked immunosorbent assay.

### Claim 49 (depends on 46)

The method of claim 46, wherein said cultured cells are cultured human NCI-H292 pulmonary mucoepidermoid carcinoma cells.
